Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

XTL Biopharmaceuticals Ltd.

www.xtlbio.com

Latest From XTL Biopharmaceuticals Ltd.

Deals Shaping The Medical Industry (01/2012)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Recent Tech Transfer Deals (12/2011)

Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.

BioPharmaceutical Medical Device

Start-Up Quarterly Statistics, Q1 2010

Highlights from the Q1 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $331 million, a 66% drop from the previous quarter's $976 million, and a 52% slide from Q1 2009. As was the case in Q4 2009, Series B rounds dominated in the biopharma and device sectors. Just one acquisition closed in the quarter - BioMarin buying LEAD Therapeutics - however two others are in the works. On the alliance front, SpePharm and Dicerna each signed two deals in Q1.
BioPharmaceutical Medical Device

Market Insight - Hepatitis C: in search of a breakthrough

Infection with the hepatitis C virus (HCV) represents an important healthcare problem worldwide. Current estimates suggest that globally about 170 million people, representing approximately 3% of the world's population, are chronically infected, and are at risk of developing liver cirrhosis and/or hepatocellular carcinoma. Estimates indicate that in the US, three to four million people are infected annually. The prevalence of HCV-related disease is increasing, but no vaccine is yet available.

Infectious Diseases Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Xenograft Technologies Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • XTL Biopharmaceuticals Ltd.
  • Senior Management
  • David Grossman, CEO
    Ronen Twito, CFO
  • Contact Info
  • XTL Biopharmaceuticals Ltd.
    Phone: 9-955-7080
    85 Medinat Hayehudim St.
    Herzliya Pituach, NY 46766
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register